Michael J Binks1, Sarah A Moberley2, Anne Balloch3, Amanda J Leach2, Sandra Nelson4, Kim M Hare2, Cate Wilson2, Peter S Morris2, Jane Nelson2, Mark D Chatfield2, Mimi L K Tang3, Paul Torzillo5, Jonathan R Carapetis6, E Kim Mulholland3, Ross M Andrews2. 1. Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia. Electronic address: Michael.Binks@menzies.edu.au. 2. Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia. 3. Murdoch Childrens Research Institute, Melbourne, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia; Royal Children's Hospital, Melbourne, VIC, Australia. 4. Department of Health and Families, Darwin, NT, Australia. 5. Royal Prince Alfred Hospital, Sydney, NSW, Australia. 6. Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
Abstract
BACKGROUND: We assessed maternal 23-valent pneumococcal polysaccharide (23vPPV) vaccine efficacy (VE) against middle ear disease and pneumococcal carriage amongst Australian Indigenous infants. METHODS: In an open label, allocation concealed, outcome-assessor blinded, community stratified, randomised controlled trial, healthy pregnant Indigenous women aged 17-39 years in the Northern Territory of Australia received the23vPPV (1:1:1) at: 30-36 weeks gestation, birth, or were unvaccinated (ClinicalTrials.gov NCT00714064). Co-primary outcomes were the point prevalences of infant middle ear disease and 23vPPV-type carriage at age 7 months. RESULTS: The consent rate was 50% (313/632). Among 227 eligible participants randomised, retention rates were 86% (66/77) controls; 89% (67/75) pregnancy vaccinees; 88% (66/75) birth vaccinees. At infant age 7 months, ear disease prevalence was: 71% (47/66) controls, 63% (42/67) pregnancy vaccinees, 76% (50/66) birth vaccinees; and 23vPPV-type carriage was: 26% (17/66) controls, 18% (12/67) pregnancy vaccinees, 18% (12/66) birth vaccinees. For pregnancy vaccinees, VE was 12% (95% CI -12% to 31%) against infant ear disease and 30% (95% CI -34% to 64%) against 23vPPV-type carriage. In a post-hoc analysis, VE against infant ear disease concurrent with carriage of 23vPPV or related types was 51% (95% CI -2% to 76%). There were no serious adverse effects following receipt of the 23vPPV in pregnancy or at birth. CONCLUSIONS: In a high risk population, our study was unable to demonstrate efficacy of 23vPPV in pregnancy against the co-primary outcomes of either all-cause infant ear disease or 23vPPV-type nasopharyngeal carriage at age 7 months. Efficacy against ear disease concurrent with carriage of vaccine-related serotypes (a more specific outcome) suggests 23vPPV in pregnancy may complement childhood pneumococcal vaccination programs.
RCT Entities:
BACKGROUND: We assessed maternal 23-valent pneumococcal polysaccharide (23vPPV) vaccine efficacy (VE) against middle ear disease and pneumococcal carriage amongst Australian Indigenous infants. METHODS: In an open label, allocation concealed, outcome-assessor blinded, community stratified, randomised controlled trial, healthy pregnant Indigenous women aged 17-39 years in the Northern Territory of Australia received the 23vPPV (1:1:1) at: 30-36 weeks gestation, birth, or were unvaccinated (ClinicalTrials.gov NCT00714064). Co-primary outcomes were the point prevalences of infantmiddle ear disease and 23vPPV-type carriage at age 7 months. RESULTS: The consent rate was 50% (313/632). Among 227 eligible participants randomised, retention rates were 86% (66/77) controls; 89% (67/75) pregnancy vaccinees; 88% (66/75) birth vaccinees. At infant age 7 months, ear disease prevalence was: 71% (47/66) controls, 63% (42/67) pregnancy vaccinees, 76% (50/66) birth vaccinees; and 23vPPV-type carriage was: 26% (17/66) controls, 18% (12/67) pregnancy vaccinees, 18% (12/66) birth vaccinees. For pregnancy vaccinees, VE was 12% (95% CI -12% to 31%) against infantear disease and 30% (95% CI -34% to 64%) against 23vPPV-type carriage. In a post-hoc analysis, VE against infantear disease concurrent with carriage of 23vPPV or related types was 51% (95% CI -2% to 76%). There were no serious adverse effects following receipt of the 23vPPV in pregnancy or at birth. CONCLUSIONS: In a high risk population, our study was unable to demonstrate efficacy of 23vPPV in pregnancy against the co-primary outcomes of either all-cause infantear disease or 23vPPV-type nasopharyngeal carriage at age 7 months. Efficacy against ear disease concurrent with carriage of vaccine-related serotypes (a more specific outcome) suggests 23vPPV in pregnancy may complement childhood pneumococcal vaccination programs.
Authors: Mark R Alderson; Tim Murphy; Stephen I Pelton; Laura A Novotny; Laura L Hammitt; Arwa Kurabi; Jian-Dong Li; Ruth B Thornton; Lea-Ann S Kirkham Journal: Int J Pediatr Otorhinolaryngol Date: 2019-12-18 Impact factor: 1.675
Authors: Amanda Jane Leach; Edward Kim Mulholland; Mathuram Santosham; Paul John Torzillo; Peter McIntyre; Heidi Smith-Vaughan; Nicole Wilson; Beth Arrowsmith; Jemima Beissbarth; Mark D Chatfield; Victor M Oguoma; Peter Stanley Morris Journal: BMC Pediatr Date: 2021-03-08 Impact factor: 2.125
Authors: Nusrat Homaira; Michael Binks; Gregory Walker; Natasha Larter; Katrina Clark; Megan Campbell; Lisa McHugh; Nancy Briggs; Joyce Nyiro; Sacha Stelzer-Braid; Nan Hu; Kristine Macartney; Tom Snelling; Saad B Omer; William Rawlinson; Ross Andrews; Adam Jaffe Journal: J Med Virol Date: 2021-10-16 Impact factor: 20.693
Authors: Kenny Chan; Phyllis Carosone-Link; Mary Thatcher G Bautista; Diozele Sanvictores; Kristin Uhler; Veronica Tallo; Marilla G Lucero; Joanne De Jesus; Eric A F Simoes Journal: BMJ Open Date: 2021-02-17 Impact factor: 3.006
Authors: Jemima Beissbarth; Heidi C Smith-Vaughan; Allen C Cheng; Peter S Morris; Amanda J Leach Journal: Front Pediatr Date: 2022-04-14 Impact factor: 3.418
Authors: Kelly M Martinovich; Elke J Seppanen; Amy S Bleakley; Sharon L Clark; Ross M Andrews; Peter C Richmond; Michael J Binks; Ruth B Thornton; Lea-Ann S Kirkham Journal: Front Immunol Date: 2022-09-21 Impact factor: 8.786
Authors: Paul V Licciardi; Edwin Hoe; Zheng Quan Toh; Anne Balloch; Sarah Moberley; Paula Binks; Rachel Marimla; Amanda Leach; Sue Skull; Kim Mulholland; Ross Andrews Journal: Clin Transl Immunology Date: 2017-10-06
Authors: Michael J Binks; Sarah A Moberley; Anne Balloch; Amanda J Leach; Sandra Nelson; Kim M Hare; Cate Wilson; Jane Nelson; Peter S Morris; Robert S Ware; Mimi L K Tang; Paul J Torzillo; Jonathan R Carapetis; Kim Mulholland; Ross M Andrews Journal: Pneumonia (Nathan) Date: 2018-12-25
Authors: Anne B Chang; Maree Toombs; Mark D Chatfield; Remai Mitchell; Siew M Fong; Michael J Binks; Heidi Smith-Vaughan; Susan J Pizzutto; Karin Lust; Peter S Morris; Julie M Marchant; Stephanie T Yerkovich; Hannah O'Farrell; Paul J Torzillo; Carolyn Maclennan; David Simon; Holger W Unger; Hasthika Ellepola; Jens Odendahl; Helen S Marshall; Geeta K Swamy; Keith Grimwood Journal: Front Pediatr Date: 2022-01-17 Impact factor: 3.418